These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

344 related items for PubMed ID: 23227123

  • 1. Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging.
    Solorio L, Olear AM, Hamilton JI, Patel RB, Beiswenger AC, Wallace JE, Zhou H, Exner AA.
    Theranostics; 2012; 2(11):1064-77. PubMed ID: 23227123
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of injection site on in situ implant formation and drug release in vivo.
    Patel RB, Solorio L, Wu H, Krupka T, Exner AA.
    J Control Release; 2010 Nov 01; 147(3):350-8. PubMed ID: 20728486
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Development of poly (lactic-co-glycolic acid) (PLGA) based implants using hot melt extrusion (HME) for sustained release of drugs: The impacts of PLGA's material characteristics.
    Yang F, Stahnke R, Lawal K, Mahnen C, Duffy P, Xu S, Durig T.
    Int J Pharm; 2024 Sep 30; 663():124556. PubMed ID: 39122196
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Lysozyme release and polymer erosion behavior of injectable implants prepared from PLGA-PEG block copolymers and PLGA/PLGA-PEG blends.
    Vesna Milacic VM, Schwendeman SP.
    Pharm Res; 2014 Feb 30; 31(2):436-48. PubMed ID: 23959854
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. In situ forming risperidone implants: Effect of PLGA attributes on product performance.
    Wang X, Bao Q, Wang R, Kwok O, Maurus K, Wang Y, Qin B, Burgess DJ.
    J Control Release; 2023 Sep 30; 361():777-791. PubMed ID: 37591464
    [Abstract] [Full Text] [Related]

  • 15. In-situ forming PLGA implants: Towards less toxic solvents.
    Ramos F, Willart JF, Neut C, Agossa K, Siepmann J, Siepmann F.
    Int J Pharm; 2024 May 25; 657():124121. PubMed ID: 38621617
    [Abstract] [Full Text] [Related]

  • 16. In-situ forming PLGA implants for intraocular dexamethasone delivery.
    Bode C, Kranz H, Siepmann F, Siepmann J.
    Int J Pharm; 2018 Sep 05; 548(1):337-348. PubMed ID: 29981408
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ultrasound-induced degradation of PLA and PLGA during microsphere processing: influence of formulation variables.
    Reich G.
    Eur J Pharm Biopharm; 1998 Mar 05; 45(2):165-71. PubMed ID: 9704913
    [Abstract] [Full Text] [Related]

  • 20. Improved design and characterization of PLGA/PLA-coated Chitosan based micro-implants for controlled release of hydrophilic drugs.
    Manna S, Donnell AM, Kaval N, Al-Rjoub MF, Augsburger JJ, Banerjee RK.
    Int J Pharm; 2018 Aug 25; 547(1-2):122-132. PubMed ID: 29857096
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.